Pfizer Canada Defeats Neupogen Patent Claims On Obviousness
Company Now Holds NOC For Nivestym Filgrastim Biosimilar
With a biosimilar to Amgen’s Neupogen already on the market in the US, Pfizer has challenged key claims of Amgen’s Canadian drug substance patent, in an attempt to clear a path to market for its Nivestym biosimilar.
You may also be interested in...
Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.